Author: Bill Snyder
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Apr. 2, 2020—VUMC is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.
Mar. 23, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Mar. 18, 2020—Last week, France’s health ministry urged people who have been infected by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) to avoid taking over-the- counter nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and aspirin because they might increase the severity of the infection.
Mar. 18, 2020—Jennifer Doudna, PhD, who led development of the revolutionary genome editing technology known as CRISPR-Cas9, is the recipient of the 2020 Vanderbilt Prize in Biomedical Science, officials at Vanderbilt University Medical Center announced this week.
Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Mar. 12, 2020—Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:
Mar. 4, 2020—Susan Amara, PhD, scientific director of the Intramural Research Program at the National Institute of Mental Health (NIMH) and an expert on the biology of neurotransmitter transporters, will deliver the next Flexner Discovery Lecture on Thursday, March 12.
Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Feb. 26, 2020—An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.